In­vestors — and As­traZeneca CEO Pas­cal So­ri­ot — are get­ting a tad ner­vous as MYS­TIC da­ta loom

As­traZeneca is get­ting close to see­ing how the dice stop rolling on its all-im­por­tant MYS­TIC tri­al, and the CEO and a whole lot of in­vestors are clear­ly start­ing to fret over the bot­tom line.

Reuters is re­port­ing this week that in­vestors have be­gun to take de­fen­sive po­si­tions on the stock in the op­tions mar­ket. And some are wor­ried that they re­al­ly won’t know what As­traZeneca’s po­si­tion in the lung can­cer mar­ket will be un­til they see all the hard da­ta from Phase III.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER